Journal of the American Society of Hypertension
Volume 4, Issue 5 , Pages 219-226, September 2010

Effects of the renin inhibitor MK-8141 (ACT-077825) in patients with hypertension

  • Charlotte Jones-Burton, MD, MS

      Affiliations

    • Merck Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, New Jersey, USA
    • Corresponding Author InformationCorresponding Author: Charlotte Jones-Burton, MD, MS, Merck Sharp and Dohme Corp., RY 34-A258, 126 East Lincoln Avenue, Rahway, NJ 07065. Tel: 732-594-7686; fax: 215-661-6757.
    • ,
  • Joseph Rubino, MBA

      Affiliations

    • Merck Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, New Jersey, USA
    • ,
  • Sophie Roy, PhD

      Affiliations

    • Merck Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, New Jersey, USA
    • ,
  • Yabing Mai, PhD

      Affiliations

    • Merck Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, New Jersey, USA
    • ,
  • Alan Meehan, PhD

      Affiliations

    • Merck Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, New Jersey, USA
    • ,
  • Marc Bellet, MD

      Affiliations

    • Actelion Pharmaceuticals Ltd., Allschwil, Switzerland
    • ,
  • Peter Feig, MD

      Affiliations

    • Merck Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, New Jersey, USA

Received 24 May 2010; accepted 24 June 2010. published online 13 August 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This study was jointly funded by Merck & Co. Inc. and Actelion Pharmaceuticals Ltd. C. Jones-Burton, J. Rubino, S. Roy, Y. Mai, A. Meehan, and P. Feig are employees of Merck, Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc., and may hold stock/stock options in the company. M. Bellet is an employee of Actelion Pharmaceuticals Ltd.

PII: S1933-1711(10)00125-7

doi:10.1016/j.jash.2010.06.006

Journal of the American Society of Hypertension
Volume 4, Issue 5 , Pages 219-226, September 2010

Article Tools

* Image Usage & Resolution